Karyopharm Therapeutics Inc.
KPTI
|
$1.16
-9.38%
-10.34%
1.4M
|
Health Technology
(0.0% 1d) (-17.6% 1m) (-71.4% 1y) (-8.6% 2d) (-15.2% 3d) (1.3% 7d) (10.39% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 133,477,816
http://www.karyopharm.com
Sec Filling | Patents | 347 employees
(US) Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
cancer autoimmunity glass treatment msa nuclear
Drugs
XPOVIO (selinexor)add to watch list Paper trade email alert is off
Press-releases
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-01 (Crawled : 20:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -1.9%
H: 0.65%
C: -10.0%
nasdaq grants therapeutics
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.26%
H: 18.38%
C: 12.5%
biopharma global
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Published: 2024-02-29 (Crawled : 12:30) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.0%
H: 2.26%
C: -12.78%
company year financial results
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Published: 2024-02-22 (Crawled : 15:30) - biospace.com/
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.83%
H: 2.05%
C: -7.38%
report year financial results
PARP Inhibitors Market to reach over USD 10.31 billion by the year 2031 - Exclusive Report by InsightAce Analytic
Published: 2024-02-21 (Crawled : 09:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.88%
H: 1.75%
C: -0.29%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -1.65%
H: 3.36%
C: 1.68%
CKPT | $1.47 -8.13% -8.84% 760K
|
Health Technology
|
| O: 0.0%
H: 1.26%
C: -3.03%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.01%
H: 1.1%
C: 1.1%
report year reach market
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 1.08%
H: 18.52%
C: 14.29%
nasdaq grants therapeutics
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.14%
H: 10.9%
C: 9.56%
revenue
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 12:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.98%
H: 1.1%
C: -8.45%
conference
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-02 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.98%
H: 1.1%
C: -8.45%
nasdaq grants therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10